64 related articles for article (PubMed ID: 12437315)
1. Therapeutic options for the management of type 2 diabetes mellitus.
Takiya L; Chawla S
Am J Manag Care; 2002 Nov; 8(11):1009-23; quiz 1024-7. PubMed ID: 12437315
[TBL] [Abstract][Full Text] [Related]
2. Oral pharmacologic management of type 2 diabetes.
Riddle MC
Am Fam Physician; 1999 Dec; 60(9):2613-20. PubMed ID: 10605995
[TBL] [Abstract][Full Text] [Related]
3. [Therapy decision based on the glucose triad. Drug treatment of type 2 diabetes].
Hanefeld M; Fischer S
MMW Fortschr Med; 2003 Feb; 145(9):30-4. PubMed ID: 12666526
[TBL] [Abstract][Full Text] [Related]
4. [Continuation 50. Type 2 diabetes: possibilities and limitations of pharmacological therapy].
Kellerer M; Jakob S; Linn T; Haslbeck M
MMW Fortschr Med; 2003 Dec; 145(51-52):I-X; quiz XI-XII. PubMed ID: 14974337
[No Abstract] [Full Text] [Related]
5. [Alpha-glucosidase inhibitor for type 2 diabetic patients. Clinical study with miglitol].
Fehmann HC
MMW Fortschr Med; 2000 May; 142(21):55. PubMed ID: 10872296
[No Abstract] [Full Text] [Related]
6. Type 2 diabetes: glycemic targets and oral therapies for older patients.
Lardinois CK
Geriatrics; 1998 Nov; 53(11):22-3, 27-8, 33-4 passim. PubMed ID: 9824974
[TBL] [Abstract][Full Text] [Related]
7. A new era in type 2 diabetes mellitus treatment?
Laws A
Am J Med; 2001 Jul; 111(1):71-2. PubMed ID: 11448665
[No Abstract] [Full Text] [Related]
8. Managing type 2 diabetes: going beyond glycemic control.
Stolar MW; Hoogwerf BJ; Gorshow SM; Boyle PJ; Wales DO
J Manag Care Pharm; 2008 Jun; 14(5 Suppl B):s2-19. PubMed ID: 18597582
[TBL] [Abstract][Full Text] [Related]
9. New concepts in diabetes: how multihormonal regulation can improve glycemic control.
Blonde L; Baker DE; Davis SN; Ratner RE
J Manag Care Pharm; 2004 Dec; 10(6 Suppl B):S3-8; quiz S9, S11-2. PubMed ID: 23570175
[TBL] [Abstract][Full Text] [Related]
10. Miglitol for type 2 diabetes mellitus.
Med Lett Drugs Ther; 1999 May; 41(1053):49-50. PubMed ID: 10368700
[No Abstract] [Full Text] [Related]
11. Potential pharmacokinetics interference between alpha-glucosidase inhibitors and other oral antidiabetic agents.
Scheen AJ; Lefèbvre PJ
Diabetes Care; 2002 Jan; 25(1):247-8. PubMed ID: 11772929
[No Abstract] [Full Text] [Related]
12. Impact of initiating insulin glargine disposable pen versus vial/syringe on real-world glycemic outcomes and persistence among patients with type 2 diabetes mellitus in a large managed care plan: a claims database analysis.
Xie L; Zhou S; Pinsky BW; Buysman EK; Baser O
Diabetes Technol Ther; 2014 Sep; 16(9):567-75. PubMed ID: 24735083
[TBL] [Abstract][Full Text] [Related]
13. [Drug therapy of type 2 diabetes: insulin sensitizers improve results].
Stadler HJ
Pflege Z; 1999 Nov; 52(11):772-5. PubMed ID: 10788929
[No Abstract] [Full Text] [Related]
14. Promising new approaches.
Reasner CA
Diabetes Obes Metab; 1999 May; 1 Suppl 1():S41-8. PubMed ID: 11220287
[TBL] [Abstract][Full Text] [Related]
15. Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.
Triplitt C; Glass L; Miyazaki Y; Wajcberg E; Gastaldelli A; De Filippis E; Cersosimo E; DeFronzo RA
Diabetes Care; 2006 Nov; 29(11):2371-7. PubMed ID: 17065670
[TBL] [Abstract][Full Text] [Related]
16. Miglitol and hepatotoxicity in type 2 diabetes mellitus.
Carlson RF
Am Fam Physician; 2000 Jul; 62(2):315, 318. PubMed ID: 10929699
[No Abstract] [Full Text] [Related]
17. Sitagliptin: a novel drug for the treatment of type 2 diabetes.
Choy M; Lam S
Cardiol Rev; 2007; 15(5):264-71. PubMed ID: 17700385
[TBL] [Abstract][Full Text] [Related]
18. A double-blind randomized study comparing the effects of continuing or not continuing rosiglitazone + metformin therapy when starting insulin therapy in people with Type 2 diabetes.
Home PD; Bailey CJ; Donaldson J; Chen H; Stewart MW
Diabet Med; 2007 Jun; 24(6):618-25. PubMed ID: 17403121
[TBL] [Abstract][Full Text] [Related]
19. Pioglitazone and rosiglitazone for diabetes.
Drug Ther Bull; 2001 Sep; 39(9):65-8. PubMed ID: 11586802
[TBL] [Abstract][Full Text] [Related]
20. A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US.
St Charles M; Minshall ME; Pandya BJ; Baran RW; Tunis SL
Curr Med Res Opin; 2009 Jun; 25(6):1343-53. PubMed ID: 19419339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
